Gleave ME - Search Results

1

Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.

Tam KJ, Liu L, Hsing M, Dalal K, Thaper D, McConeghy B, Yenki P, Bhasin S, Peacock JW, Wang Y, Cherkasov A, Rennie PS, Gleave ME, Ong CJ. Tam KJ, et al. Among authors: gleave me. Sci Rep. 2024 Mar 25;14(1):7082. doi: 10.1038/s41598-024-57854-w. Sci Rep. 2024. PMID: 38528115 Free PMC article.

2

[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].

Bruchovsky N, Goldenberg SL, Rennie PS, Gleave M. Bruchovsky N, et al. Urologe A. 1995 Sep;34(5):389-92. Urologe A. 1995. PMID: 7483155 Review. German.

3

Control of tumor progression by maintenance of apoptosis.

Bruchovsky N, Snoek R, Rennie PS, Akakura K, Goldenberg LS, Gleave M. Bruchovsky N, et al. Prostate Suppl. 1996;6:13-21. Prostate Suppl. 1996. PMID: 8630223 Review.

4

[Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].

Gleave M, Santo N, Rennie PS, Goldenberg SL, Bruchovsky N, Sullivan LD. Gleave M, et al. Prog Urol. 1996 Jun;6(3):375-85. Prog Urol. 1996. PMID: 8763692 French.

5

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Sato N, et al. Among authors: gleave me. J Steroid Biochem Mol Biol. 1996 May;58(2):139-46. doi: 10.1016/0960-0760(96)00018-0. J Steroid Biochem Mol Biol. 1996. PMID: 8809195

6

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. Sato N, et al. Among authors: gleave me. Cancer Res. 1997 Apr 15;57(8):1584-9. Cancer Res. 1997. PMID: 9108464

7

Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP.

Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME. Sato N, et al. Among authors: gleave me. J Biol Chem. 1997 Jul 11;272(28):17485-94. doi: 10.1074/jbc.272.28.17485. J Biol Chem. 1997. PMID: 9211894 Free article.

8

Differential transactivation by the androgen receptor in prostate cancer cells.

Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave M, Sato N, Mawji NR, Rennie PS. Snoek R, et al. Prostate. 1998 Sep 1;36(4):256-63. doi: 10.1002/(sici)1097-0045(19980901)36:4<256::aid-pros7>3.0.co;2-d. Prostate. 1998. PMID: 9719026

9

Intermittent androgen suppression for prostate cancer: rationale and clinical experience.

Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Gleave M, et al. Eur Urol. 1998;34 Suppl 3:37-41. doi: 10.1159/000052297. Eur Urol. 1998. PMID: 9854195 Review.

10

Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.

Miyake H, Nelson C, Rennie PS, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 2000 Jan 1;60(1):170-6. Cancer Res. 2000. PMID: 10646870

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

574 results

Search Page

Filters